555 related articles for article (PubMed ID: 28622463)
1. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
[TBL] [Abstract][Full Text] [Related]
2. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
[TBL] [Abstract][Full Text] [Related]
3. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
[TBL] [Abstract][Full Text] [Related]
4. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
[TBL] [Abstract][Full Text] [Related]
5. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
Genovese M; Westhovens R; Meuleners L; Van der Aa A; Harrison P; Tasset C; Kavanaugh A
Arthritis Res Ther; 2018 Mar; 20(1):57. PubMed ID: 29566740
[TBL] [Abstract][Full Text] [Related]
6. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.
Kremer JM; Emery P; Camp HS; Friedman A; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S; Keystone EC
Arthritis Rheumatol; 2016 Dec; 68(12):2867-2877. PubMed ID: 27389975
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Genovese MC; Smolen JS; Weinblatt ME; Burmester GR; Meerwein S; Camp HS; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S
Arthritis Rheumatol; 2016 Dec; 68(12):2857-2866. PubMed ID: 27390150
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Namour F; Diderichsen PM; Cox E; Vayssière B; Van der Aa A; Tasset C; Van't Klooster G
Clin Pharmacokinet; 2015 Aug; 54(8):859-74. PubMed ID: 25681059
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
[TBL] [Abstract][Full Text] [Related]
10. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Combe B; Kivitz A; Tanaka Y; van der Heijde D; Simon JA; Baraf HSB; Kumar U; Matzkies F; Bartok B; Ye L; Guo Y; Tasset C; Sundy JS; Jahreis A; Genovese MC; Mozaffarian N; Landewé RBM; Bae SC; Keystone EC; Nash P
Ann Rheum Dis; 2021 Jul; 80(7):848-858. PubMed ID: 33504485
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2020 Jun; 58(6):293-298. PubMed ID: 32301699
[TBL] [Abstract][Full Text] [Related]
12. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
[TBL] [Abstract][Full Text] [Related]
13. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.
Genovese MC; van Vollenhoven RF; Pacheco-Tena C; Zhang Y; Kinnman N
Arthritis Rheumatol; 2016 Jan; 68(1):46-55. PubMed ID: 26473751
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
Atsumi T; Tanaka Y; Matsubara T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Westhovens R; Ching DWT; Messina OD; Burmester GR; Bartok B; Pechonkina A; Kondo A; Yin Z; Guo Y; Tasset C; Sundy JS; Takeuchi T
Mod Rheumatol; 2022 Feb; 32(2):273-283. PubMed ID: 34910203
[TBL] [Abstract][Full Text] [Related]
15. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
Westhovens R; Rigby WFC; van der Heijde D; Ching DWT; Stohl W; Kay J; Chopra A; Bartok B; Matzkies F; Yin Z; Guo Y; Tasset C; Sundy JS; Jahreis A; Mozaffarian N; Messina OD; Landewé RB; Atsumi T; Burmester GR
Ann Rheum Dis; 2021 Jun; 80(6):727-738. PubMed ID: 33452004
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
17. Filgotinib for the treatment of rheumatoid arthritis.
Taylor PC; Abdul Azeez M; Kiriakidis S
Expert Opin Investig Drugs; 2017 Oct; 26(10):1181-1187. PubMed ID: 28838249
[TBL] [Abstract][Full Text] [Related]
18. Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Namour F; Desrivot J; Van der Aa A; Harrison P; Tasset C; van't Klooster G
Drug Metab Lett; 2016; 10(1):38-48. PubMed ID: 26693854
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
Tanaka Y; Matsubara T; Atsumi T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Combe BG; Kivitz AJ; Bae SC; Keystone EC; Nash P; Matzkies F; Bartok B; Pechonkina A; Kondo A; Ye L; Guo Y; Tasset C; Sundy JS; Takeuchi T
Mod Rheumatol; 2022 Feb; 32(2):263-272. PubMed ID: 34910188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
